Customer demanded validation of a new preclinical fibrosis model
| Reference number | |
| Coordinator | INFICURE BIO AKTIEBOLAG - InfiCure Bio AB |
| Funding from Vinnova | SEK 298 722 |
| Project duration | April 2017 - June 2017 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovativa startups fas 1 Våren 2017 |
Important results from the project
The aim of the project was to generate data on the N-IF mouse model in order to be able to respond to questions asked by potential customers. A question asked by many potential customers at interviews is if we know how the drug pirfenidone, used to treat pulmonary fibrosis, affect the liver fibrosis in the N-IF mouse model. The goal of this project was to be able to answer this question and by completing this project, we have been able to achieve this goal.
Expected long term effects
Our treatment of the N-IF mouse model with pirfenidone has shown that this drug has little or no effect on the liver fibrosis in the model. These results are expected, since pirfenidone is a drug for treatment of pulmonary fibrosis, and in addition, this drug has weak effects on pulmonary fibrosis. Our potential customers have requested this experiment since pirfenidone is one of few fibrosis drugs available on the market today, but since the drug treats pulmonary fibrosis, with limited effect on the human disease, no or very minor effects on the liver fibrosis are expected in our model.
Approach and implementation
Two groups of N-IF mice have been used in this project. One group of mice were treated with pirfenidone and the other group was treated with vehicle. At the end of the treatment period, all mice were sacrificed and organs of interest were harvested. Analysis were done to elucidate if there were differences in levels of fibrosis between the two treatment groups. Treatment of the mice and execution of the analyzes has been running according to the plan, which has resulted in a successful project.